MivInvestments Inc. has initiated an independent bullish technical trading alert for 11/20/09 on Echo Therapeutics, Inc. (OTC:ECTE.OB). Shares of the company finished the day at $1.35, up 8.15% from the opening bell on heavy buying pressure. The excitement was due to the announcement on positive results of a clinical study testing symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes. Despite the fact that there has been a recent common shares financing scheduled, companies usually take their time and let the price consolidate before engaging in these activities, thus a short-term buy could be a smart investment. Towards the end of this alert a technical analysis will also be issued.

According to the ADA, the cost of diabetes care in the United States in

ImmunoGen, Inc. (NASDAQ:IMGN) has announced that Amgen, Inc. (NASDAQ:AMGN)Inc has licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology for the development of anticancer therapeutics to an undisclosed target. This is the second such license to be taken by Amgen – the company licensed the exclusive right to use ImmunoGen’s TAP technology for another undisclosed cancer target in September 2009.

Amgen Inc. is one of the leading biotechnology companies that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company markets human therapeutic products in the areas of supportive cancer care, nephrology and inflammation. While announcing the news, CEO

Neuromed and CombinatoRx, Incorporated (NASDAQ:CRXX)has agreed to sign a definitive merger agreement valued $28.8 million USD on 30th June, 2009 according to a news published by the RTT News.

Although the “merger” declaration with privately held Neuromeds Pharmaceutical Inc. did give a much required market boost, premarket trades for CombinatoRx Inc fell by 34 pct as reported by Reuters November 16th, 2009.

Regardless of the market fall for CombinatoRx, both companies are still sticking to the merger agreement and expected to close the transaction on 22nd November, 2009. Coincidentally, a pain killer drug “Exalgo” announced by Neuromed is in its current form not sufficient for approval under Section 505(b)(1) of the Food, Drug and Cosmetic Act of 1938, as amended (FDCA)

Exalgo, developed by ALZA

Sucampo Pharma Europe Ltd, a subsidiary of Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) has announced that Swissmedic has granted a marketing authorization for Amitiza 24 mcg gel capsules for the long term treatment of patients with chronic idiopathic constipation (CIC). This decision by Swissmedic marks an important milestone in Sucampo’s global development and commercialization plan of lubiprostone for CIC, IBS-C and other indications. Amitiza is a local activator of type-2 chloride channels in cells lining the small intestine. It increases fluid secretion into the intestinal tract which softens the stool, facilitating intestinal motility and bowel movements. The type 2 chloride channels also play an important role in the restoration of tight junction complexes and in the recovery of barrier function in the

Pay day loans may sound like the perfect solution when you have an emergency or just need some extra cash. It sounds easy: no credit check, no assets to pledge, and no waiting. But is a pay day loan a life saver or a death trap?

Pay day loans got their name because people would run out of cash between paychecks. A loan was made until pay day when it would be paid back. Now pay day loans, also called cash advance loans, means a loan that is granted immediately, doesn’t rely on a credit score, and isn’t secured on assets. The loans can be granted in as little as 30 minutes. The catch is that the fees are high. The interest rate is usually

Exelixis, Inc (NASDAQ:EXEL) has announced and reported that the interim data from an ongoing Phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid tumors have displayed positive results. XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Exelixis has entered into a global license agreement with Sanofi-Aventis for XL147. Exelixis’ President of Research and Development, Michael M. Morrissey has mentioned that the preclinical data suggest that XL147 potentiates the antitumor efficacy of paclitaxel and carboplatin without exacerbating the toxicity of this commonly used regimen. Additionally, he also mentioned that they are very encouraged by this emerging

ImmunoGen, Inc (NASDAQ:IMGN) have reported the clinical data of their IMGN901 product candidate which will be used for the treatment of Merkel cell carcinoma (MCC). The Company mentioned that the meaningful evidence of anti-cancer activity has been noted in limited number of patients who are suffering from MCC and who have received IMGN901. The findings were reported at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, MA, and suggest development for metastatic MCC could be a potential registration path for IMGN901. MCC is an aggressive neuroendocrine cancer of the skin that typically occurs on the head or neck, most often in individuals of European ancestry. However, each year there are about 1400 cases of MCC diagnosed in the United States each year and the

The poor economy, bad real estate conditions, and lackluster job market have forced many families into a precarious financial position. They can’t get a loan based on the value of their house because the house isn’t worth what it’s mortgaged for. Getting a better paying job isn’t an option at the moment. So if money is needed are there loan options for those with poor credit?

An asset based loan is one solution. If you have an auto that is free and clear from liens and has some value it may be possible to get a loan using the car as an asset. The problem is that since you have poor credit that loan isn’t going to be from a traditional lending source.

There are companies that will

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/17/09 on Sinobiopharma Inc (OTC:SNBP) Inc. has initiated an independent bullish technical trading alert for 11/17/09 on Sinobiopharma, Inc. (OTC:SNBP.OB). Shares of the company finished the day at $0.25, up 38.89% from the opening bell on heavy buying pressure. The turning point in the share price which had been experiencing a down trend for well over a year, resulted from record volume totalling 2,911,677 which trumped the volume average of 265,000.

Investors have begun to feel a renewed sense of optimism towards the company on the eve of their recent press release. Sinobiopharma

In a recent article titled Zevotek Poised to Explode Like Spongetech Delivery Systems?, I discussed the explosive growth potential for Zevotek, Inc. (OTC:ZVTK) and compared its potential growth to Spongetech (OTC:SPNG). It is notable that the stock has nearly doubled within two trading days since the article was published. However, the legitimate question that remains on the minds of many “does Zevotek, Inc. really have it in it to continue to grow as a stock?”

Consumers aren’t only becoming more environmentally aware, but they are also becoming more energy efficient and aware of the health of effects of their home products. For example, on Zevotek’s Ionic Bulb with Air Purifier, I found the reviews of a few customers to give the product five stars/five, all stating